Sugi Predict

Sugi Predict / Compounds / SCHEMBL7472158

SCHEMBL7472158

SCHEMBL7472158

Cc1oncc1-c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDO2 P48775 7/20 0.59
▸ MAPT P10636 2/20 0.58
▸ L3MBTL1 Q9Y468 2/20 0.58
▸ ALDH1A1 P00352 3/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ HPGD P15428 2/20 0.46
▸ LMNA P02545 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ BRD4 O60885 3/20 0.44
▸ AKT1 P31749 1/20 0.44
▸ AKT2 P31751 1/20 0.44
▸ BRD2 P25440 1/20 0.44
▸ PTGS1 P23219 2/20 0.42
▸ PTGS2 P35354 2/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ GAA P10253 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ PSMB5 P28074 1/20 0.38
▸ CYP2A6 P11509 1/20 0.38
▸ CYP2B6 P20813 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22637149 0.83 TDO2 (0.51) TDO2MAPTL3MBTL1ALDH1A1KDM4E
SCHEMBL29430767 0.83 TDO2 (0.51) TDO2MAPTL3MBTL1ALDH1A1KDM4E
SCHEMBL26868062 0.83 L3MBTL1 (0.42) TDO2MAPTL3MBTL1ALDH1A1KDM4E
SCHEMBL19367737 0.81 MAPT (0.45) TDO2MAPTL3MBTL1ALDH1A1KDM4E
SCHEMBL19367739 0.79 TDO2 (0.61) TDO2MAPTL3MBTL1ALDH1A1KDM4E
SCHEMBL19367731 0.79 TDO2 (0.61) TDO2MAPTL3MBTL1HPGDLMNA
SCHEMBL31398256 0.79 MAPT (0.41) TDO2MAPTL3MBTL1ALDH1A1KDM4E
SCHEMBL31198523 0.77 MAP4K4 (0.53) TDO2MAPTL3MBTL1ALDH1A1KDM4E
SCHEMBL739660 0.76 TDO2 (0.61) TDO2MAPTL3MBTL1LMNAAKT1
SCHEMBL25094361 0.75 KIF11 (0.47) TDO2MAPTL3MBTL1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1883627-B1 BIR DOMAIN BINDING COMPOUNDS PHARMASCIENCE INC (CA) 2018-04-18 — — EP disclosed
US-9365614-B2 IAP BIR domain binding compounds PHARMASCIENCE INC. (CA) 2016-06-14 — — US disclosed
US-8980837-B2 Inhibitors of IAP GENENTECH, INC. (US) 2015-03-17 — — US disclosed
US-8980837-B2 Inhibitors of IAP GENENTECH, INC. (US) 2015-03-17 — — US disclosed
US-8907092-B2 Inhibitors of IAP GENENTECH, INC. (US) 2014-12-09 — — US disclosed
US-8907092-B2 Inhibitors of IAP GENENTECH, INC. (US) 2014-12-09 — — US disclosed
US-20140336134-A1 IAP BIR Domain Binding Compounds PHARMASCIENCE INC. (CA) 2014-11-13 — — US disclosed
US-8765681-B2 IAP BIR domain binding compounds PHARMASCIENCE INC. (CA) 2014-07-01 — — US disclosed
US-8648094-B2 IAP BIR domain binding compounds PHARMASCIENCE, INC. (CA) 2014-02-11 — — US disclosed
US-8575113-B2 BIR domain binding compounds PHARMASCIENCE INC. (CA) 2013-11-05 — — US disclosed
US-20080009485-A1 Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis WYETH (US) 2008-01-10 — — US disclosed
US-20070299052-A1 Inhibitors of IAP GENENTECH, INC. (US) 2007-12-27 — — US disclosed
US-20070299052-A1 Inhibitors of IAP GENENTECH, INC. (US) 2007-12-27 — — US disclosed
US-20070219140-A1 IAP BIR domain binding compounds AEGERA THERAPEUTICS, INC. (CA) 2007-09-20 — — US disclosed
US-7244851-B2 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies GENENTECH, INC. (US) 2007-07-17 — — US disclosed
US-7244851-B2 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies GENENTECH, INC. (US) 2007-07-17 — — US disclosed
US-20070093428-A1 Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; AEGERA THERAPEUTICS, INC. (CA) 2007-04-26 — — US disclosed
US-20070093429-A1 IAP BIR domain binding compounds AEGERA THERAPEUTICS, INC. (CA) 2007-04-26 — — US disclosed
EP-0809636-B1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-04 — — EP disclosed
EP-1223167-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle & Co. (US) 2002-07-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093429-A1 IAP BIR domain binding compounds BIRC5, BIRC2, BIRC3 TDO2 4167/4885MAPT 376/4885L3MBTL1 317/4885
US-20080009485-A1 Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis PLA2G12A, PLA2G1B, PLA2G5 TDO2 505/4885MAPT 4878/4885L3MBTL1 3294/4885
US-20070093428-A1 Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; BAD, BIRC5, BAX TDO2 4196/4885MAPT 778/4885L3MBTL1 1026/4885
US-20140336134-A1 IAP BIR Domain Binding Compounds BIRC2, BIRC7, BIRC5 TDO2 4593/4885MAPT 912/4885L3MBTL1 1788/4885
US-20070299052-A1 Inhibitors of IAP XIAP, BIRC5, BIRC3 TDO2 4611/4885MAPT 2274/4885L3MBTL1 317/4885
US-20070219140-A1 IAP BIR domain binding compounds BIRC5, BIRC2, BIRC8 TDO2 4150/4885MAPT 314/4885L3MBTL1 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.